

Fax

RECEIVED
CENTRAL FAX CENTER

JAN 03 2005

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

Date: 5 November 2004

To: Hope Robinson
Company: USPTO Tech Center 1600
Fax: 703-872-9306
571-273-0957

From: Greg Cox
Fax: 317-276-5172
Phone: 317-277-2620

Privileged and Confidential Communication

Total Pages: 8

Subject: 09/868,974; Shelf-Stable Formulation of Glucagon-Like Peptide-1

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

RECEIVED
CENTRAL FAX CENTER

LILLY PATENT DIVISION Fax:317-276-5172

Jan 3 2005 14:13

P.02

JAN 03 2005

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

JAN FOWLER

Type or print name of person signing certification

Jan Fowler

Signature

1/3/05

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: Mark L. Brader, et al.)	
Serial No.	: 09/868,974)	
Filed	: December 21, 1999)	Group Art Unit:
)	1653
For	: Shelf-Stable Formulation of)	
	Glucagon-Like Peptide-1)	Examiner:
)	H. Robinson
Docket No.	: X-11869)	

RESPONSE AFTER FINAL REJECTION AND AMENDMENT
UNDER 37 C.F.R. 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

This paper is filed in response to the Examiner's Final Rejection of Claims 27-30, 33-37, 40-44 and 47. Please cancel Claims 27-30, 33, 35, and 42. Claims 34, 36, 37, 40, 41, 43, 44, and 47 are currently pending in the Application. Applicants respectfully request that the Examiner enter the following amendments that Applicants believe place the application in condition for allowance.

Amendments to Claims are presented on page 2 and page 3 of this paper.

Remarks and Arguments begin on page 5 of this paper.

Summary and Conclusion begins on page 7 of this paper.